PMID- 33983847
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR  - 20220117
IS  - 1557-7732 (Electronic)
IS  - 1080-7683 (Print)
IS  - 1080-7683 (Linking)
VI  - 37
IP  - 6
DP  - 2021 Jul-Aug
TI  - Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital.
PG  - 338-342
LID - 10.1089/jop.2020.0112 [doi]
AB  - Purpose: To analyze the efficacy, safety, and accessibility of netarsudil 0.02% 
      in patients with glaucoma (suspect, open or closed) at a safety-net academic 
      medical center, Boston Medical Center (BMC). Methods: Retrospective chart review 
      of patients prescribed netarsudil 0.02% for uncontrolled glaucoma at BMC between 
      December 2017 and September 2019. Outcome measures included change in intraocular 
      pressure (IOP) from baseline and evaluation of adverse events (AEs). Results: One 
      hundred thirty patients (60% severe stage) were analyzed. The IOP reduction from 
      baseline was about 3 mmHg. Fifty-four patients (42%) experienced an AE (eg, 
      conjunctival hyperemia). Thirty-eight patients (29%) started netarsudil 0.02% in 
      lieu of laser or surgery. Ninety-nine patients (71%) required prior authorization 
      for insurance coverage of netarsudil 0.02%. Ten patients (7%) were unable to 
      obtain netarsudil 0.02% due to issues with insurance coverage. Conclusion: 
      Netarsudil 0.02% yielded significant IOP reduction in our cohort, however, to a 
      smaller degree compared with prior studies that bore equivocal IOP reduction 
      regardless of baseline IOP. Conjunctival hyperemia was the most common AE. In a 
      limited number of patients, netarsudil 0.02% was not covered by insurance.
FAU - Fridman, Gabrielle
AU  - Fridman G
AUID- ORCID: 0000-0002-2065-4568
AD  - Department of Ophthalmology, Boston Medical Center/Boston University School of 
      Medicine, Boston, Massachusetts, USA.
FAU - Sadlak, Natalie
AU  - Sadlak N
AD  - Department of Ophthalmology, Boston Medical Center/Boston University School of 
      Medicine, Boston, Massachusetts, USA.
FAU - Eliassi-Rad, Babak
AU  - Eliassi-Rad B
AD  - Department of Ophthalmology, Boston Medical Center/Boston University School of 
      Medicine, Boston, Massachusetts, USA.
FAU - Desai, Manishi A
AU  - Desai MA
AD  - Department of Ophthalmology, Boston Medical Center/Boston University School of 
      Medicine, Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
DEP - 20210513
PL  - United States
TA  - J Ocul Pharmacol Ther
JT  - Journal of ocular pharmacology and therapeutics : the official journal of the 
      Association for Ocular Pharmacology and Therapeutics
JID - 9511091
RN  - 0 (Benzoates)
RN  - 11P2JDE17B (beta-Alanine)
RN  - W6I5QDT7QI (netarsudil)
SB  - IM
MH  - Aged
MH  - Benzoates/*therapeutic use
MH  - Female
MH  - Glaucoma/classification/*drug therapy/pathology
MH  - Humans
MH  - *Intraocular Pressure
MH  - Male
MH  - Retrospective Studies
MH  - Safety-net Providers
MH  - Treatment Outcome
MH  - beta-Alanine/*analogs & derivatives/therapeutic use
PMC - PMC8328041
OTO - NOTNLM
OT  - glaucoma
OT  - intraocular pressure
OT  - netarsudil
OT  - ocular hypertension
OT  - rho kinase inhibitor
COIS- No competing financial interests exist.
EDAT- 2021/05/14 06:00
MHDA- 2022/01/18 06:00
PMCR- 2021/07/28
CRDT- 2021/05/13 17:15
PHST- 2021/05/14 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
PHST- 2021/05/13 17:15 [entrez]
PHST- 2021/07/28 00:00 [pmc-release]
AID - 10.1089/jop.2020.0112 [pii]
AID - 10.1089/jop.2020.0112 [doi]
PST - ppublish
SO  - J Ocul Pharmacol Ther. 2021 Jul-Aug;37(6):338-342. doi: 10.1089/jop.2020.0112. 
      Epub 2021 May 13.